Access the full text.
Sign up today, get DeepDyve free for 14 days.
S. Loi, S. Michiels, D. Lambrechts, D. Fumagalli, B. Claes, P. Kellokumpu-Lehtinen, P. Bono, V. Kataja, M. Piccart, H. Joensuu, C. Sotiriou (2013)
Somatic Mutation Profiling and Associations With Prognosis and Trastuzumab Benefit in Early Breast CancerJNCI Journal of the National Cancer Institute, 105
S. Loi, Benjamin Haibe-Kains, S. Majjaj, F. Lallemand, V. Durbecq, D. Larsimont, A. González-Angulo, L. Pusztai, W. Symmans, A. Bardelli, P. Ellis, A. Tutt, C. Gillett, B. Hennessy, G. Mills, W. Phillips, M. Piccart, T. Speed, G. McArthur, C. Sotiriou (2010)
PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor–positive breast cancerProceedings of the National Academy of Sciences, 107
T. Dogruluk, Y. Tsang, M. Espitia, Fengju Chen, Tenghui Chen, Zechen Chong, V. Appadurai, Armel Dogruluk, A. Eterovic, P. Bonnen, C. Creighton, Ken Chen, G. Mills, K. Scott (2015)
Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.Cancer research, 75 24
L. Saal, K. Holm, M. Maurer, L. Memeo, T. Su, Xiaomei Wang, Jennifer Yu, P. Malmström, M. Mansukhani, J. Enoksson, H. Hibshoosh, Å. Borg, R. Parsons (2005)
PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma.Cancer research, 65 7
L. Cantley (2002)
The phosphoinositide 3-kinase pathway.Science, 296 5573
R. Brough, J. Frankum, D. Sims, A. Mackay, A. Mendes-Pereira, I. Bajrami, Sara Costa-Cabral, Rumana Rafiq, Amar Ahmad, M. Cerone, R. Natrajan, R. Sharpe, K. Shiu, D. Wetterskog, K. Dedes, Maryou Lambros, Teeara Rawjee, S. Linardopoulos, J. Reis-Filho, N. Turner, C. Lord, A. Ashworth (2011)
Functional viability profiles of breast cancer.Cancer discovery, 1 3
A. Bader, Sohye Kang, P. Vogt (2006)
Cancer-specific mutations in PIK3CA are oncogenic in vivoProceedings of the National Academy of Sciences of the United States of America, 103
Sohye Kang, A. Bader, P. Vogt (2005)
Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic.Proceedings of the National Academy of Sciences of the United States of America, 102 3
L. Cantley, K. Auger, C. Carpenter, B. Duckworth, A. Graziani, R. Kapeller, S. Soltoff (1991)
Oncogenes and signal transductionCell, 64
N. Miled, Ying Yan, W. Hon, O. Perisic, M. Zvelebil, Y. Inbar, D. Schneidman-Duhovny, H. Wolfson, J. Backer, Roger Williams (2007)
Mechanism of Two Classes of Cancer Mutations in the Phosphoinositide 3-Kinase Catalytic SubunitScience, 317
P. Cossu-rocca, S. Orrù, M. Muroni, Francesca Sanges, G. Sotgiu, S. Ena, G. Pira, Luciano Murgia, A. Manca, M. Uras, M. Sarobba, S. Urru, M. Miglio (2015)
Analysis of PIK3CA Mutations and Activation Pathways in Triple Negative Breast CancerPLoS ONE, 10
M. Kriegsmann, V. Endris, Thomas Wolf, N. Pfarr, A. Stenzinger, S. Loibl, C. Denkert, A. Schneeweiss, J. Budczies, P. Sinn, W. Weichert (2014)
Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differencesOncotarget, 5
K. Kalinsky, A. Heguy, U. Bhanot, S. Patil, M. Moynahan (2011)
PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progressionBreast Cancer Research and Treatment, 129
S. Goel, I. Krop (2015)
Deciphering the role of phosphatidylinositol 3-kinase mutations in human epidermal growth factor receptor 2-positive breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 12
G. Hortobagyi (2015)
Everolimus Plus Exemestane for the Treatment of Advanced Breast Cancer: A Review of Subanalyses from BOLERO-2Neoplasia (New York, N.Y.), 17
S. Hurvitz, F. André, Zefei Jiang, Z. Shao, M. Mano, S. Neciosup, L. Tseng, Qingyuan Zhang, K. Shen, Donggeng Liu, L. Dreosti, H. Burris, M. Toi, M. Buyse, David Cabaribere, M. Lindsay, S. Rao, L. Pacaud, T. Taran, D. Slamon (2015)
Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.The Lancet. Oncology, 16 7
J. Baselga, J. Cortés, S. Im, E. Clark, G. Ross, A. Kiermaier, S. Swain (2014)
Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32 33
M. Ellis, C. Perou (2013)
The genomic landscape of breast cancer as a therapeutic roadmap.Cancer discovery, 3 1
Diana Ramirez-Ardila, J. Helmijr, M. Look, I. Lurkin, K. Ruigrok-Ritstier, S. Laere, L. Dirix, F. Sweep, P. Span, S. Linn, J. Foekens, S. Sleijfer, E. Berns, M. Jansen (2013)
Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifenBreast Cancer Research and Treatment, 139
S. Boyault, Y. Drouet, C. Navarro, T. Bachelot, C. Lasset, I. Treilleux, E. Tabone, A. Puisieux, Qing Wang (2012)
Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypesBreast Cancer Research and Treatment, 132
Jie-hua He, Roujun Peng, Zhongyu Yuan, Shusen Wang, Jiewen Peng, G. Lin, Xiaomei Jiang, T. Qin (2012)
Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarrayMedical Oncology, 29
J. Jensen, A. Laenkholm, A. Knoop, M. Ewertz, R. Bandaru, Weihua Liu, W. Hackl, J. Barrett, H. Gardner, J. Jensen (2010)
PIK3CA Mutations May Be Discordant between Primary and Corresponding Metastatic Disease in Breast CancerClinical Cancer Research, 17
P. De, Yuling Sun, J. Carlson, L. Friedman, B. Leyland-Jones, N. Dey (2014)
Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness.Neoplasia, 16 1
YR Liu (2014)
PIK3CA mutations define favorable prognostic biomarkers in operable breast cancer: a systematic review and meta-analysisOncol Targets Ther, 7
S. Loibl, G. Minckwitz, A. Schneeweiss, S. Paepke, A. Lehmann, M. Rezai, D. Zahm, P. Sinn, F. Khandan, H. Eidtmann, Karel Dohnal, C. Heinrichs, J. Huober, B. Pfitzner, P. Fasching, F. André, J. Lindner, C. Sotiriou, August Dykgers, Sanxing Guo, S. Gade, V. Nekljudova, S. Loi, M. Untch, C. Denkert (2014)
PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32 29
Magdalena Čížková, Aurélie Susini, S. Vacher, G. Cizeron‐Clairac, C. Andrieu, K. Driouch, E. Fourme, R. Lidereau, I. Bièche (2012)
PIK3CA mutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroupsBreast Cancer Research : BCR, 14
B. Lehmann, Joshua Bauer, J. Schafer, Christopher Pendleton, Luojia Tang, Kimberly Johnson, Xi Chen, J. Balko, H. Gómez, C. Arteaga, G. Mills, M. Sanders, J. Pietenpol (2014)
PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitorsBreast Cancer Research : BCR, 16
E. López-Knowles, Corrinne Segal, Q. Gao, I. Garcia-Murillas, N. Turner, I. Smith, L. Martin, M. Dowsett (2014)
Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibitionBreast Cancer Research : BCR, 16
I. Majewski, P. Nuciforo, L. Mittempergher, A. Bosma, H. Eidtmann, E. Holmes, C. Sotiriou, D. Fumagalli, J. Jiménez, C. Aura, L. Prudkin, Maria Díaz-Delgado, L. Peña, S. Loi, C. Ellis, N. Schultz, E. Azambuja, N. Harbeck, M. Piccart-Gebhart, R. Bernards, J. Baselga (2015)
PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 12
J. Engelman, Ji Luo, L. Cantley (2006)
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolismNature Reviews Genetics, 7
P. Eichhorn, M. Gili, M. Scaltriti, V. Serra, M. Guzman, Wouter Nijkamp, R. Beijersbergen, Vanesa Valero, J. Seoane, R. Bernards, J. Baselga (2008)
Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.Cancer research, 68 22
A. Hanker, A. Pfefferle, J. Balko, M. Kuba, C. Young, V. Sanchez, Cammie Sutton, Hailing Cheng, C. Perou, Jean Zhao, R. Cook, C. Arteaga (2013)
Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapiesProceedings of the National Academy of Sciences, 110
A. Markou, S. Farkona, Christina Schiza, Tonia Efstathiou, S. Kounelis, N. Malamos, V. Georgoulias, E. Lianidou (2014)
PIK3CA Mutational Status in Circulating Tumor Cells Can Change During Disease Recurrence or Progression in Patients with Breast CancerClinical Cancer Research, 20
M. Troxell, Alayne Brunner, T. Neff, A. Warrick, C. Beadling, K. Montgomery, Shirley Zhu, C. Corless, R. West (2012)
Phosphatidylinositol-3-kinase pathway mutations are common in breast columnar cell lesionsModern Pathology, 25
C. García-echeverría, W. Sellers (2008)
Drug discovery approaches targeting the PI3K/Akt pathway in cancerOncogene, 27
V. Abramson, M. Lloyd, T. Ballinger, M. Sanders, L. Du, Darson Lai, Zengliu Su, I. Mayer, M. Levy, D. LaFrance, C. Vnencak-Jones, Y. Shyr, K. Dahlman, W. Pao, C. Arteaga (2014)
Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profilingBreast Cancer Research and Treatment, 145
T. Takeshita, Y. Omoto, M. Yamamoto-Ibusuki, Yutaka Yamamoto, H. Iwase (2013)
Clinical significance of androgen receptor and its phosphorylated form in breast cancer.Endocrine-related cancer, 20 5
V. Sabine, C. Crozier, C. Brookes, Camilla Drake, T. Piper, C. Velde, A. Hasenburg, D. Kieback, C. Markopoulos, L. Dirix, C. Seynaeve, D. Rea, J. Bartlett (2014)
Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32 27
A. Philp, I. Campbell, C. Leet, E. Vincan, S. Rockman, R. Whitehead, Robert Thomas, W. Phillips (2001)
The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors.Cancer research, 61 20
C. Mihalcea, A. Moroșanu, D. Murăraşu, L. Puiu, S. Cinca, S. Voinea, N. Mirancea (2016)
Particular molecular and ultrastructural aspects in invasive mammary carcinoma.Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie, 56 4
K. Pogue-Geile, N. Song, Jong-Hyeon Jeong, P. Gavin, Seong-Rim Kim, Nicole Blackmon, Melanie Finnigan, P. Rastogi, L. Fehrenbacher, E. Mamounas, S. Swain, D. Wickerham, C. Geyer, J. Costantino, N. Wolmark, S. Paik (2015)
Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 12
A. Bosch, Zhiqiang Li, A. Bergamaschi, H. Ellis, Eneda Toska, A. Prat, Jessica Tao, D. Spratt, Nerissa Viola-Villegas, P. Castel, Gerard Minuesa, N. Morse, J. Rodón, Y. Ibrahim, J. Cortés, J. Peréz-García, P. Galván, J. Grueso, M. Guzman, J. Katzenellenbogen, Michael Kharas, Jason Lewis, M. Dickler, V. Serra, N. Rosen, S. Chandarlapaty, M. Scaltriti, J. Baselga (2015)
PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancerScience Translational Medicine, 7
K. Berns, H. Horlings, B. Hennessy, M. Madiredjo, E. Hijmans, K. Beelen, S. Linn, A. González-Angulo, K. Stemke‐Hale, M. Hauptmann, R. Beijersbergen, G. Mills, M. Vijver, R. Bernards (2007)
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.Cancer cell, 12 4
K. Stemke‐Hale, A. González-Angulo, A. Lluch, R. Neve, W. Kuo, M. Davies, M. Carey, Zhi Hu, Y. Guan, A. Sahin, W. Symmans, L. Pusztai, L. Nolden, H. Horlings, K. Berns, M. Hung, M. Vijver, V. Valero, J. Gray, R. Bernards, G. Mills, B. Hennessy (2008)
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.Cancer research, 68 15
G. Papaxoinis, V. Kotoula, Z. Alexopoulou, K. Kalogeras, F. Zagouri, E. Timotheadou, H. Gogas, G. Pentheroudakis, C. Christodoulou, A. Koutras, D. Bafaloukos, G. Aravantinos, P. Papakostas, E. Charalambous, K. Papadopoulou, I. Varthalitis, I. Efstratiou, T. Zaramboukas, H. Patsea, C. Scopa, M. Skondra, P. Kosmidis, D. Pectasides, G. Fountzilas (2015)
Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) StudyPLoS ONE, 10
S. Loi, S. Michiels, J. Baselga, John Bartlett, John Bartlett, S. Singhal, V. Sabine, A. Sims, T. Sahmoud, J. Dixon, M. Piccart, C. Sotiriou (2013)
PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast CancerPLoS ONE, 8
M. Barbareschi, F. Buttitta, L. Felicioni, S. Cotrupi, Fabio Barassi, Maela Grammastro, A. Ferro, P. Palma, E. Galligioni, A. Marchetti (2007)
Different Prognostic Roles of Mutations in the Helical and Kinase Domains of the PIK3CA Gene in Breast CarcinomasClinical Cancer Research, 13
Jean Zhao, Zhenning Liu, Li Wang, Eyoung Shin, M. Loda, T. Roberts (2005)
The oncogenic properties of mutant p110α and p110β phosphatidylinositol 3-kinases in human mammary epithelial cellsProceedings of the National Academy of Sciences of the United States of America, 102
Amit Kumar, O. Fernandez-Capetillo, A. Carrera (2010)
Nuclear phosphoinositide 3-kinase β controls double-strand break DNA repairProceedings of the National Academy of Sciences, 107
R. Katso, K. Okkenhaug, K. Ahmadi, S. White, J. Timms, M. Waterfield (2001)
Cellular function of phosphoinositide 3-kinases: Implications for development, immunity, homeostasis, and cancerAnnual Review of Cell and Developmental Biology, 17
A. Chakrabarty, N. Bhola, Cammie Sutton, R. Ghosh, M. Kuba, B. Dave, Jenny Chang, C. Arteaga (2013)
Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors.Cancer research, 73 3
D. Koboldt, R. Fulton, M. McLellan, Heather Schmidt, Joelle Kalicki-Veizer, Joshua McMichael, L. Fulton, D. Dooling, L. Ding, E. Mardis, R. Wilson, Adrian Ally, M. Balasundaram, Y. Butterfield, R. Carlsen, Candace Carter, Andy Chu, E. Chuah, Hye-Jung Chun, R. Coope, Noreen Dhalla, R. Guin, Carrie Hirst, M. Hirst, R. Holt, Darlene Lee, H. Li, Michael Mayo, Richard Moore, A. Mungall, E. Pleasance, A. Robertson, J. Schein, A. Shafiei, Payal Sipahimalani, Jared Slobodan, D. Stoll, Angela Tam, N. Thiessen, R. Varhol, N. Wye, Thomas Zeng, Yongjun Zhao, I. Birol, Steven Jones, M. Marra, A. Cherniack, G. Saksena, R. Onofrio, Nam Pho, S. Carter, S. Schumacher, B. Tabak, Bryan Hernandez, Jeff Gentry, Huy Nguyen, A. Crenshaw, K. Ardlie, R. Beroukhim, W. Winckler, G. Getz, S. Gabriel, M. Meyerson, L. Chin, R. Kucherlapati, K. Hoadley, J. Auman, C. Fan, Yidi Turman, Yan Shi, Ling Li, M. Topal, Xiaping He, H. Chao, A. Prat, Grace Silva, M. Iglesia, Wei Zhao, Jerry Usary, J. Berg, Michael Adams, J. Booker, Junyuan Wu, Anisha Gulabani, T. Bodenheimer, A. Hoyle, J. Simons, Matthew Soloway, Lisle Mose, S. Jefferys, S. Balu, J. Parker, D. Hayes, C. Perou, Simeen Malik, S. Mahurkar, Hui Shen, D. Weisenberger, T. Triche, Phillip Lai, M. Bootwalla, D. Maglinte, B. Berman, D. Berg, S. Baylin, P. Laird, C. Creighton, L. Donehower, M. Noble, Douglas Voet, N. Gehlenborg, D. Cara, Juinhua Zhang, Hailei Zhang, Chang-Jiun Wu, Spring Liu, M. Lawrence, L. Zou, A. Sivachenko, Pei Lin, P. Stojanov, R. Jing, Juok Cho, Raktim Sinha, R. Park, Marc-Danie Nazaire, James Robinson, H. Thorvaldsdóttir, J. Mesirov, P. Park, Sheila Reynolds, R. Kreisberg, Brady Bernard, Ryan Bressler, Timo Erkkilä, Jake Lin, V. Thorsson, Wei Zhang, I. Shmulevich, G. Ciriello, Nils Weinhold, N. Schultz, Jianjiong Gao, E. Cerami, Benjamin Gross, A. Jacobsen, Rileen Sinha, B. Aksoy, Yevgeniy Antipin, B. Reva, R. Shen, B. Taylor, M. Ladanyi, C. Sander, Pavana Anur, P. Spellman, Yiling Lu, Wenbin Liu, R. Verhaak, G. Mills, R. Akbani, Nianxiang Zhang, B. Broom, Tod Casasent, Chris Wakefield, A. Unruh, K. Baggerly, K. Coombes, J. Weinstein, D. Haussler, C. Benz, Joshua Stuart, S. Benz, Jingchun Zhu, C. Szeto, G. Scott, C. Yau, Evan Paull, Daniel Carlin, Christopher Wong, Artem Sokolov, J. Thusberg, S. Mooney, S. Ng, Theodore Goldstein, K. Ellrott, Mia Grifford, C. Wilks, Singer Ma, Brian Craft, Chunhua Yan, Ying Hu, D. Meerzaman, J. Gastier-Foster, Jay Bowen, N. Ramirez, Aaron Black, R. Pyatt, P. White, E. Zmuda, J. Frick, T. Lichtenberg, Robin Brookens, Myra George, M. Gerken, H. Harper, K. Leraas, L. Wise, Teresa Tabler, Cynthia McAllister, T. Barr, Melissa Hart-Kothari, Katherine Tarvin, Charles Saller, G. Sandusky, Colleen Mitchell, M. Iacocca, Jennifer Brown, B. Rabeno, Christine Czerwinski, N. Petrelli, Oleg Dolzhansky, M. Abramov, Olga Voronina, O. Potapova, J. Marks, W. Suchorska, D. Murawa, W. Kycler, Matthew Ibbs, Konstanty Korski, A. Spychała, P. Murawa, Jacek Brzeziński, Hanna Perz, Radoslaw Łaźniak, M. Teresiak, Honorata Tatka, E. Leporowska, M. Bogusz-Czerniewicz, J. Malicki, A. Mackiewicz, M. Wiznerowicz, X. Le, B. Kohl, N. Tien, Richard Thorp, N. Bang, H. Sussman, Bui Phu, R. Hajek, N. Hung, H. Thang, K. Khan, R. Penny, D. Mallery, Erin Curley, C. Shelton, P. Yena, J. Ingle, F. Couch, W. Lingle, T. King, A. González-Angulo, Mary Dyer, Shuying Liu, Xiaolong Meng, Modesto Patangan, F. Waldman, H. Stoppler, W. Rathmell, L. Thorne, Meijuan Huang, L. Boice, Ashley Hill, C. Morrison, Carmelo Gaudioso, W. Bshara, K. Daily, Sophie Egea, M. Pegram, C. Gomez-Fernandez, R. Dhir, R. Bhargava, A. Brufsky, C. Shriver, J. Hooke, J. Campbell, R. Mural, Hai Hu, S. Somiari, C. Larson, B. Deyarmin, L. Kvecher, A. Kovatich, M. Ellis, T. Stricker, K. White, O. Olopade, C. Luo, Y. Chen, R. Bose, Li-Wei Chang, Andrew Beck, T. Pihl, M. Jensen, R. Sfeir, A. Kahn, A. Chu, Prachi Kothiyal, Zhining Wang, E. Snyder, J. Pontius, Brenda Ayala, M. Backus, Jessica Walton, J. Baboud, D. Berton, M. Nicholls, Deepak Srinivasan, R. Raman, Stanley Girshik, Peter Kigonya, S. Alonso, Rashmi Sanbhadti, S. Barletta, D. Pot, Margi Sheth, John Demchok, K. Shaw, Liming Yang, G. Eley, M. Ferguson, R. Tarnuzzer, J. Zhang, Laura Dillon, K. Buetow, P. Fielding, B. Ozenberger, M. Guyer, H. Sofia, Jacqueline Palchik (2012)
Comprehensive molecular portraits of human breast tumorsNature, 490
S. Loi, S. Loi, S. Michiels, S. Michiels, R. Salgado, N. Sirtaine, V. Jose, D. Fumagalli, P. Kellokumpu-Lehtinen, P. Bono, V. Kataja, C. Desmedt, M. Piccart, S. Loibl, C. Denkert, M. Smyth, H. Joensuu, C. Sotiriou (2014)
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.Annals of oncology : official journal of the European Society for Medical Oncology, 25 8
S Loi (2013)
Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancerJ Natl Cancer Inst, 105
T. Takeshita, Yutaka Yamamoto, M. Yamamoto-Ibusuki, Toko Inao, Aiko Sueta, Saori Fujiwara, Y. Omoto, H. Iwase (2015)
Prognostic role of PIK3CA mutations of cell‐free DNA in early‐stage triple negative breast cancerCancer Science, 106
B. Pang, Shi Cheng, Shipeng Sun, Cheng An, Zhi-Yuan Liu, Xue Feng, Guijian Liu (2014)
Prognostic role of PIK3CA mutations and their association with hormone receptor expression in breast cancer: a meta-analysisScientific Reports, 4
I. Treilleux, M. Arnedos, C. Cropet, Q. Wang, J. Ferrero, S. Abadie-Lacourtoisie, C. Lévy, E. Legouffe, A. Lortholary, E. Pujade-Lauraine, A. Bourcier, J. Eymard, D. Spaeth, T. Bachelot (2015)
Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer.Annals of oncology : official journal of the European Society for Medical Oncology, 26 1
K. Beelen, M. Opdam, T. Severson, R. Koornstra, A. Vincent, J. Wesseling, J. Muris, E. Berns, J. Vermorken, P. Diest, S. Linn (2014)
PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patientsBreast Cancer Research : BCR, 16
F. André, R. O'Regan, M. Ozguroglu, M. Toi, Bing-he Xu, G. Jerusalem, N. Masuda, S. Wilks, F. Arena, C. Isaacs, Y. Yap, Z. Pápai, I. Láng, A. Armstrong, G. Lerzo, M. White, K. Shen, J. Litton, David Chen, Yufen Zhang, S. Ali, T. Taran, L. Gianni (2014)
Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial.The Lancet. Oncology, 15 6
Yirong Liu, Yizhou Jiang, W. Zuo, Keda Yu, Z. Shao (2014)
PIK3CA mutations define favorable prognostic biomarkers in operable breast cancer: a systematic review and meta-analysisOncoTargets and therapy, 7
N. Maruyama, Y. Miyoshi, T. Taguchi, Y. Tamaki, M. Monden, S. Noguchi (2007)
Clinicopathologic Analysis of Breast Cancers with PIK3CA Mutations in Japanese WomenClinical Cancer Research, 13
R. Sakr, B. Weigelt, S. Chandarlapaty, V. Andrade, E. Guerini-Rocco, D. Giri, C. Ng, C. Cowell, N. Rosen, J. Reis-Filho, T. King (2014)
PI3K Pathway Activation in High-Grade Ductal Carcinoma In Situ—Implications for Progression to Invasive Breast CarcinomaClinical Cancer Research, 20
A. Miron, M. Váradi, D. Carrasco, Hailun Li, Lauren Luongo, Hee Kim, S. Park, E. Cho, Gretchen Lewis, Sarah Kehoe, J. Iglehart, D. Dillon, D. Allred, L. Macconaill, R. Gelman, K. Polyak (2010)
PIK3CA mutations in in situ and invasive breast carcinomas.Cancer research, 70 14
D. Tang, Shanqin Xu, Qingyuan Zhang, Wen-Wu Zhao (2012)
The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancerMedical Oncology, 29
G. Kao, Zibin Jiang, A. Fernandes, Anjali Gupta, A. Maity (2007)
Inhibition of Phosphatidylinositol-3-OH Kinase/Akt Signaling Impairs DNA Repair in Glioblastoma Cells following Ionizing Radiation*Journal of Biological Chemistry, 282
Glenn Deng, S. Krishnakumar, A. Powell, Haiyu Zhang, M. Mindrinos, M. Telli, Ronald Davis, S. Jeffrey (2014)
Single cell mutational analysis of PIK3CA in circulating tumor cells and metastases in breast cancer reveals heterogeneity, discordance, and mutation persistence in cultured disseminated tumor cells from bone marrowBMC Cancer, 14
Yardena Samuels, Zhenghe Wang, A. Bardelli, N. Silliman, J. Ptak, Steve Szabo, Hai Yan, A. Gazdar, S. Powell, G. Riggins, J. Willson, S. Markowitz, K. Kinzler, B. Vogelstein, V. Velculescu (2004)
High Frequency of Mutations of the PIK3CA Gene in Human CancersScience, 304
Christiane Knuefermann, Yang Lu, Bolin Liu, W. Jin, K. Liang, Ling-Chia Wu, Mathias Schmidt, G. Mills, J. Mendelsohn, Z. Fan (2003)
HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cellsOncogene, 22
PIK3CA is one of the most commonly mutated oncogenes in breast cancer, albeit at variable distribution among the different biological subtypes. Overall, it appears that PIK3CA mutations are most likely found in tumors with less aggressive characteristics, especially estrogen receptor (ER)-positive, luminal A tumors. Studies assessing its prognostic or predictive role have reported conflicting data, in part due to different methodologies used for detection and small sample sizes. The majority of reports used retrospective data from clinical trials thus could not exclude the effect of treatment heterogeneity when evaluating prognostic factors, and analysis was not subtype specific. Since breast cancer subtypes differ in terms of biology, treatment, and outcomes, it is critical that the effects of PIK3CA mutations on pathophysiology and therapy responsiveness are analyzed independently in each subtype. This short review discusses these issues and the significance of PIK3CA mutations in relation to the expression of HER2 and hormone receptors.
Current Breast Cancer Reports – Springer Journals
Published: May 20, 2016
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.